

# **CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET**


## **Product name** C3c, Human, clone F1-4

Catalog number	HM2318		
Lot number	-	Expiry date	-
Volume	1 ml	Amount	100 µg
Formulation	0.2 $\mu m$ filtered in PBS+0.1%BSA+0.02%NaN3	Concentration	100 μg/ml
Host Species	Mouse IgG1	Conjugate	None
Endotoxin	N.A.	Purification	Protein G
Storage	4°C		

#### **Application notes**

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #						1	1	1
Yes	•					•	•	٠
No								
N.D.		•	•	•	•			

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot



IHC-F: frozen human tonsil sections. Antibody HM2318 was used in a 1:100 dilution.

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

- W: A non-reduced and reduced sample treatment and SDS-Page was used. The band sizes are 26 and 140 kDa (Ref.1).
- IHC-F: Immunohistochemistry was performed with an automated, validated and accredited staining system (Ventana Benchmark ULTRA, Ventana Medical Systems, USA) using Ultraview or Optiview universal DAB detection Kit. Incubation was followed by hematoxylin II counter stain for 12 minutes and then a blue colouring reagent for 8 minutes according to the manufactures instructions.

## **General Information**

escription	Antibody F1-4 recognizes a unique epitope exclusively present on human complement C3c. The complement system mediates a number of essential biological functions that participate in host defense against infection, initiation of the inflammatory reaction, processing and clearance of immune complexes and regulation of the immune response. There are three pathways of complement activation: the classical pathway is initiated by immune complexes, the lectin pathway by surface bound mannan binding lectin and the alternative pathway by all the surfaces that are not specifically protected against it. Each of the complement pathway generates a C3 convertase, a serine protease that cleaves the central complement protein C3, and generates the major cleavage fragment C3b. C3b is an opsonin and part of one of the main convertases that drives the complement cascade. In the presence of complement regulatory molecules C3b may be further degraded sequentially to iC3b, C3c, C3dg and C3d. The disadvantage of most complement biomarkers is their short half-life, making reliable sample collection and measurements difficult. Unlike other C3 fragments, C3c does not bind to other structures, like pathogens, cell surface (receptors) and other plasma proteins. Therefore, C3c is a stable complement biomarker which will appear in the fluid phase only, without interference of other C3 based products. The measurement of C3c provides evidence of (uncontrolled) complement activation and can be
	indications that C3 is associated with the cardiovascular system and Parkinson's disease, making C3c a reliable and

www.hycultbiotech.com

D

	useful biomarker. Antibody F1-4 only reacts with C3c and does not cross-react with other C3 fragments. The antibody can be used in ELISA, western blotting and immunoprecipitation.
Immunogen	Synthetic peptide representing the last 16 C-terminal (NKTVAVRTLDPERLGR) residues of C3c alpha domain 1 coupled onto PPD (purified protein derivate, Statens Serum Institut).
Aliases	Complement component 3, C3c
References	<ol> <li>Palarasah_Y et al. Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3. J of Imm methodss 2010-362: 142.</li> </ol>
Storage&stability	Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Precautions	For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC	Date
Brenda Teunissen	25/07/2019

Do you have any questions or comments regarding this product? Please contact us via <u>support@hycultbiotech.com</u>.

# bringing innate immunity to the **next level**